Ondine Biomedical (FRA:VF5) EPS (Basic): €-0.05 (TTM As of Dec. 2024)


FRA:VF5 Ondine Biomedical Inc FRA:VF5
47 GF Score
Price €0.15
View Full Analysis

What is Ondine Biomedical EPS (Basic)?

Ondine Biomedical FRA:VF5 47 EPS (Basic) is €-0.05 as of Dec. 2024. GuruFocus rates FRA:VF5 with a GF Score™ of 47/100.

Ondine Biomedical's basic earnings per share (Basic EPS) for the six months ended in Dec. 2024 was €-0.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.05.

Ondine Biomedical's EPS (Diluted) for the six months ended in Dec. 2024 was €-0.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.05.

Ondine Biomedical's EPS without NRI for the six months ended in Dec. 2024 was €-0.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Ondine Biomedical  (FRA:VF5) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Ondine Biomedical EPS (Basic) Related Terms

Ondine Biomedical EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Ondine Biomedical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical EPS (Basic) Chart

Ondine Biomedical Annual Data
Trend Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.44 -0.07 -0.05 -0.05

Ondine Biomedical Semi-Annual Data
Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.03 -0.02 -0.02 -0.03
FRA:VF5
47GF Score
Ondine Biomedical Inc FRA:VF5
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ondine Biomedical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Ondine Biomedical's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-12.802-0)/274.601
=-0.05

Ondine Biomedical's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-7.599-0)/307.732
=-0.02

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.05 mean?
Ondine Biomedical (FRA:VF5) has a EPS (Basic) of €-0.05 as of Dec. 2024. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Ondine Biomedical and its competitors.
Is Ondine Biomedical's EPS (Basic) too high?
Ondine Biomedical's current EPS (Basic) is €-0.05. Overall, Ondine Biomedical has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's EPS (Basic) compare to VRTX and REGN?
Ondine Biomedical's EPS (Basic) of €-0.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Ondine Biomedical and its competitors. Ondine Biomedical's current EPS (Basic) is €-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Ondine Biomedical (FRA:VF5) has a current EPS (Basic) of €-0.05. The current EPS (Basic) is €-0.05. Ondine Biomedical's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current EPS (Basic) is €-0.05 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ondine Biomedical Business Description

Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
47GF Score

Get the complete analysis for FRA:VF5

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price